Outcome of ovarian cancer after breast cancer in <italic>BRCA1</italic> and <italic>BRCA2</italic> mutation carriers

Leendert H Zaaijer; Helena C van Doorn; Marian J E Mourits; Marc van Beurden; Joanne A de Hullu; Muriel A Adank; Luc R C W van Lonkhuijzen; Hans F A Vasen; Brigitte F M Slangen; Katja N Gaarenstroom; Ronald P Zweemer; Peggy M L H Vencken; Caroline Seynaeve; Mieke Kriege

首页> 外文期刊>British Journal of Cancer >Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

【24h】

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

机译： BRCA1 和 BRCA2 突变携带者患乳腺癌后卵巢癌的结果

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2 -associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. Methods: We included 386 BRCA1/2 -associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. Results: BRCA -associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HR_(mult)) 1.47; 95% confidence interval (CI) 1.03–2.08 and HR_(mult)1.43; 95% CI 1.01–2.03), and a non-significantly worse OS (HR_(mult)1.15; 95% CI 0.84–1.57) and OCSS (HR_(mult)1.18; 95% CI 0.85–1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HR_(mult)1.99; 95% CI 1.21–3.31). Conclusions: Our results suggest that BRCA1/2 -associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.

机译：背景：乳腺癌（BC）的病史是否影响BRCA1 / 2相关的上皮性卵巢癌（EOC）的结果尚不清楚。在当前分析中对此进行了调查。方法：我们纳入了1980年至2015年期间诊断出的386例BRCA1 / 2相关的EOC患者。比较了无进展生存期（PFS），无进展间隔（PFI），总生存期（OS）和卵巢癌特异性生存期（OCSS）在有或没有先前BC的EOC患者之间。结果：无论有无BC史，与BRCA相关的EOC患者的PFS和PFI均明显较差（多元危险比（HR_（mult））1.47; 95％置信区间（CI）1.03-2.08和HR_（mult）1.43 ; 95％CI 1.01–2.03），以及较差的OS（HR_（mult）1.15; 95％CI 0.84–1.57）和OCSS（HR_（mult）1.18; 95％CI 0.85–1.62）差得多。对于接受BC辅助化疗的亚组，卵巢癌特异性生存率显着降低（HR_（mult）1.99; 95％CI 1.21-3.31）。结论：我们的结果表明，BRCA1 / 2相关的EOC合并有BC的患者比没有BC的EOC患者的预后更差，尤其是在辅助化疗的情况下。

著录项

来源
《British Journal of Cancer》 |2016年第10期|共5页
作者
Leendert H Zaaijer; Helena C van Doorn; Marian J E Mourits; Marc van Beurden; Joanne A de Hullu; Muriel A Adank; Luc R C W van Lonkhuijzen; Hans F A Vasen; Brigitte F M Slangen; Katja N Gaarenstroom; Ronald P Zweemer; Peggy M L H Vencken; Caroline Seynaeve; Mieke Kriege;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers [J] . Ana Osorio, Roger L. Milne, Karoline Kuchenbaecker, PLoS Genetics . 2014,第4期

机译：涉及基础切除修复的DNA糖基酶可能与<斜斜体> BRCA1 和<斜体> BRCA2 突变载体相关的癌症风险有关
2. Use of DNA–Damaging Agents and RNA Pooling to Assess Expression Profiles Associated with BRCA1 and BRCA2 Mutation Status in Familial Breast Cancer Patients [J] . Logan C. Walker, Bryony A. Thompson, Nic Waddell, PLoS Genetics . 2010,第2期

机译：使用DNA损伤剂和RNA合并评估家族性乳腺癌患者与 BRCA1 和 BRCA2 突变状态相关的表达谱
3. Deleterious Mutations in DNA Repair Gene FANCC Exist in BRCA1/2-Negative Chinese Familial Breast and/or Ovarian Cancer Patients [J] . Zhi-Wen Pan, Xiao-Jia Wang, Tianhui Chen, Frontiers in Oncology . 2019,第4期

机译：DNA修复基因的有害突变<斜体> FANCC 在<斜体> BRCA1 / 2 - 中华族家族乳腺癌和/或卵巢癌患者中存在
4. An Integrated Microfluidic Platform for Detecting BRCA1/BRCA2 Gene Mutation and Risk Assessment of Ovarian Cancer [C] . Yu-Hung Cheng, Chih-Hung Wang, Keng-Fu Hsu, International Conference on Solid-State Sensors, Actuators and Microsystems . 2021

机译：一种用于检测BRCA1 / BRCA2基因突变和卵巢癌风险评估的集成微流体平台
5. Breast cancer risk after chemoprevention in BRCA1 versus BRCA2 mutation carriers. [D] . Shaver, Jamie. 2011

机译：BRCA1和BRCA2突变携带者进行化学预防后的乳腺癌风险。
6. Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers [O] . G. Cipollini, C. Ghimenti, E. Sensi, 1999

机译：BRCA1和BRCA2在意大利遗传性和散发性乳腺癌和卵巢癌中的突变分析：乳腺癌BRCA突变携带者的肿瘤基因型与表型相关性。
7. Germline italicPALB2/italic, italicATM/italic variants in a patient with breast and ovarian cancer at risk for familial cancer syndrome: Is there a role for risk-reducing salpingo-oophorectomy? [O] . Semiramis L. Carbajal-Mamani, Merry J. Markham, Joaquín Santolaya-Forgas, 2020

机译：种系列<斜视> PALB2 ，<斜体> ATM 具有乳腺癌和卵巢癌的患者的患者，适用于家族癌症综合征风险：是否存在风险降低的Salpingo-Oophorectomy作用？

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

摘要

著录项

相似文献

相关主题

期刊订阅